In both of these drug studies, all of the infants will be evaluated up to 1 year of age for major and minor anomalies by pediatric specialists, Dr. Chambers said.
Final results for preterm delivery, birth weight, and congenital malformations should be available in 1–2 years. In the meantime, even these small preliminary numbers are reassuring because they don't show any particular pattern.
“All the major teratogens are associated with very specific patterns of abnormal outcomes. When you don't see a pattern and you just see one of this and one of that, it makes you a little more confident that this is not an Accutane,” Dr. Chambers said.
Physicians who prescribe etanercept and adalimumab to women of childbearing age are encouraged to enroll patients in OTIS. For more information, call 877-311-8972 or e-mail Dr. Chambers at chchambers@ucsd.edu